Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, VMD PhD, Navidea Chief Executive Officer, will present at the 16th Annual BIO CEO and Investor Conference held at the Waldorf Astoria in New York City, NY on February 10-11, 2014. Dr. Pykett will provide an update on the Company and its commercial and development programs on Monday, February 10, 2014 at 1:30 pm ET. Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.veracast.com/webcasts/bio/ceoinvestor2014/28134561298.cfm. The webcast replay will be available one hour after the conclusion of the live event and will be archived for approximately 30 days. About Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and RIGScan TM, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek ® (technetium 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.